Dapoxetine

Identification

Name
Dapoxetine
Accession Number
DB04884
Type
Small Molecule
Groups
Investigational
Description

Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

Structure
Thumb
Synonyms
  • Dapoxetina
  • Dapoxetinum
External IDs
LY 210448 / LY-210448
Categories
UNII
GB2433A4M3
CAS number
119356-77-3
Weight
Average: 305.4134
Monoisotopic: 305.177964363
Chemical Formula
C21H23NO
InChI Key
USRHYDPUVLEVMC-FQEVSTJZSA-N
InChI
InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
IUPAC Name
dimethyl[(1S)-3-(naphthalen-1-yloxy)-1-phenylpropyl]amine
SMILES
CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of premature ejaculation.

Pharmacodynamics

Dapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).

Mechanism of action

The drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.

TargetActionsOrganism
U5-hydroxytryptamine receptor 1ANot AvailableHuman
U5-hydroxytryptamine receptor 1BNot AvailableHuman
U5-hydroxytryptamine receptor 2CNot AvailableHuman
Absorption

Rapidly absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Initial half-life of 1-2 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dapoxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dapoxetine.Experimental
AcarboseDapoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.Approved, Investigational
AceclofenacDapoxetine may increase the antiplatelet activities of Aceclofenac.Approved, Investigational
AcenocoumarolDapoxetine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineDapoxetine may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dapoxetine.Approved
AcetaminophenDapoxetine may increase the antiplatelet activities of Acetaminophen.Approved
Acetyl sulfisoxazoleThe serum concentration of Dapoxetine can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidDapoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Dapoxetine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dapoxetine.Approved, Investigational
AlaproclateDapoxetine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideDapoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dapoxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Dapoxetine.Approved, Illicit
AlfuzosinDapoxetine may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Dapoxetine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Dapoxetine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Almotriptan.Approved, Investigational
AlogliptinDapoxetine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Dapoxetine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Dapoxetine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapoxetine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Dapoxetine.Approved, Withdrawn
Aminosalicylic AcidDapoxetine may increase the antiplatelet activities of Aminosalicylic Acid.Approved
AmiodaroneThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dapoxetine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapoxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dapoxetine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amphetamine.Approved, Illicit, Investigational
AntipyrineDapoxetine may increase the antiplatelet activities of Antipyrine.Approved, Investigational
AntrafenineDapoxetine may increase the antiplatelet activities of Antrafenine.Approved
AprepitantThe serum concentration of Dapoxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleDapoxetine may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Dapoxetine.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dapoxetine.Approved
AsenapineDapoxetine may increase the orthostatic hypotensive activities of Asenapine.Approved
AtazanavirThe serum concentration of Dapoxetine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Dapoxetine.Approved
AtomoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atomoxetine.Approved
AvanafilDapoxetine may increase the orthostatic hypotensive activities of Avanafil.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dapoxetine.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dapoxetine.Approved
Azilsartan medoxomilDapoxetine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.Approved, Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dapoxetine.Approved
BalsalazideDapoxetine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Dapoxetine.Experimental
BenazeprilDapoxetine may increase the orthostatic hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideDapoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Dapoxetine.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dapoxetine.Approved, Investigational
BenzthiazideDapoxetine may increase the hyponatremic activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dapoxetine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Dapoxetine.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Dapoxetine.Approved, Investigational
BevantololDapoxetine may increase the orthostatic hypotensive activities of Bevantolol.Approved
BezitramideBezitramide may increase the serotonergic activities of Dapoxetine.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bifemelane.Experimental
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Dapoxetine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Dapoxetine.Investigational
BoceprevirThe serum concentration of Dapoxetine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Dapoxetine.Approved
BortezomibThe serum concentration of Dapoxetine can be increased when it is combined with Bortezomib.Approved, Investigational
BrexpiprazoleDapoxetine may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapoxetine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapoxetine.Approved, Illicit, Investigational
BromfenacDapoxetine may increase the antiplatelet activities of Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Dapoxetine.Experimental
BromocriptineDapoxetine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Dapoxetine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapoxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dapoxetine.Approved, Investigational, Withdrawn
BucindololDapoxetine may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacDapoxetine may increase the antiplatelet activities of Bufexamac.Approved, Experimental
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Dapoxetine.Experimental, Investigational
BunazosinDapoxetine may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapoxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Dapoxetine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Dapoxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dapoxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dapoxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dapoxetine.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dapoxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Dapoxetine.Approved, Illicit, Vet Approved
CanagliflozinDapoxetine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanDapoxetine may increase the orthostatic hypotensive activities of Candesartan.Experimental
Candesartan cilexetilDapoxetine may increase the orthostatic hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilDapoxetine may increase the orthostatic hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Dapoxetine.Investigational
CapsaicinDapoxetine may increase the antiplatelet activities of Capsaicin.Approved
CaptoprilDapoxetine may increase the orthostatic hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Dapoxetine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dapoxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Dapoxetine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapoxetine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Caroxazone.Withdrawn
CarprofenDapoxetine may increase the antiplatelet activities of Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Dapoxetine.Approved
CarvedilolDapoxetine may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibDapoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Dapoxetine.Approved, Investigational
CeritinibThe serum concentration of Dapoxetine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dapoxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dapoxetine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dapoxetine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dapoxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dapoxetine.Approved
ChlorothiazideDapoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Chlorphenamine.Approved
ChlorphenesinDapoxetine may increase the antiplatelet activities of Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Dapoxetine.Experimental
ChlorpromazineDapoxetine may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideDapoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine.Approved, Investigational, Withdrawn
ChlorthalidoneDapoxetine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dapoxetine.Approved
Choline magnesium trisalicylateDapoxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
CilazaprilDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.Approved
CimetidineThe metabolism of Dapoxetine can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibDapoxetine may increase the antiplatelet activities of Cimicoxib.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dapoxetine.Approved, Vet Approved
CisplatinDapoxetine may increase the antiplatelet activities of Cisplatin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Dapoxetine can be increased when it is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dapoxetine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dapoxetine.Approved, Illicit
Clodronic AcidDapoxetine may increase the antiplatelet activities of Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dapoxetine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dapoxetine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapoxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Dapoxetine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Dapoxetine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapoxetine.Approved, Illicit
ClorindioneDapoxetine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Dapoxetine.Experimental
ClotrimazoleThe serum concentration of Dapoxetine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dapoxetine.Approved
CobicistatThe serum concentration of Dapoxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cocaine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Dapoxetine.Approved, Illicit
ConivaptanThe serum concentration of Dapoxetine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Dapoxetine can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Dapoxetine can be increased when it is combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dapoxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapoxetine.Approved
CyclopenthiazideDapoxetine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Dapoxetine.Experimental
CyclosporineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Dapoxetine can be decreased when used in combination with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapoxetine.Approved, Investigational
DapagliflozinDapoxetine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleDapoxetine may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DarunavirThe serum concentration of Dapoxetine can be increased when it is combined with Darunavir.Approved
DelaprilDapoxetine may increase the orthostatic hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Dapoxetine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Dapoxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapoxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapoxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dapoxetine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine.Approved
DexibuprofenDapoxetine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexketoprofenDapoxetine may increase the antiplatelet activities of Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapoxetine.Approved, Vet Approved
DextroamphetamineDapoxetine may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Dapoxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Dapoxetine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Dapoxetine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dapoxetine.Approved, Illicit, Investigational, Vet Approved
DiclofenacDapoxetine may increase the antiplatelet activities of Diclofenac.Approved, Vet Approved
DicoumarolDapoxetine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Dapoxetine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Dapoxetine.Approved, Illicit
DiflunisalDapoxetine may increase the antiplatelet activities of Diflunisal.Approved, Investigational
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Dapoxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Dapoxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Dapoxetine.Experimental, Illicit
DiltiazemThe serum concentration of Dapoxetine can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapoxetine.Approved
DiphenadioneDapoxetine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapoxetine.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Dapoxetine.Approved, Illicit
DipyridamoleDapoxetine may increase the orthostatic hypotensive activities of Dipyridamole.Approved
DisopyramideDapoxetine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Dapoxetine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dapoxetine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Dapoxetine.Approved
DoxazosinDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.Approved, Investigational
DoxycyclineThe serum concentration of Dapoxetine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Dapoxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Dapoxetine.Experimental
DronedaroneThe serum concentration of Dapoxetine can be increased when it is combined with Dronedarone.Approved
DroperidolDapoxetine may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DrospirenoneDapoxetine may increase the antiplatelet activities of Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dapoxetine.Experimental, Illicit
DroxicamDapoxetine may increase the antiplatelet activities of Droxicam.Withdrawn
DulaglutideDapoxetine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dapoxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dapoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapoxetine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Dapoxetine.Investigational
EmpagliflozinDapoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilDapoxetine may increase the orthostatic hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatDapoxetine may increase the orthostatic hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapoxetine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dapoxetine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Dapoxetine.Experimental
EpinephrineDapoxetine may increase the orthostatic hypotensive activities of Epinephrine.Approved, Vet Approved
EpitizideDapoxetine may increase the hyponatremic activities of Epitizide.Experimental
EprosartanDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.Approved
Erythrityl TetranitrateDapoxetine may increase the orthostatic hypotensive activities of Erythrityl Tetranitrate.Approved, Investigational
ErythromycinThe serum concentration of Dapoxetine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe serum concentration of Esatenolol can be increased when it is combined with Dapoxetine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Dapoxetine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dapoxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapoxetine.Approved, Investigational
EtanerceptDapoxetine may increase the antiplatelet activities of Etanercept.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dapoxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.Approved
Ethyl biscoumacetateDapoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Dapoxetine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dapoxetine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Dapoxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dapoxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dapoxetine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dapoxetine.Approved
EtodolacDapoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Dapoxetine.Withdrawn
EtoricoxibDapoxetine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Dapoxetine.Illicit, Vet Approved
ExenatideDapoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Dapoxetine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dapoxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dapoxetine.Approved, Illicit, Withdrawn
FenfluramineDapoxetine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenDapoxetine may increase the antiplatelet activities of Fenoprofen.Approved
FentanylThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dapoxetine.Approved, Investigational
FimasartanDapoxetine may increase the orthostatic hypotensive activities of Fimasartan.Approved, Investigational
Fish oilDapoxetine may increase the antiplatelet activities of Fish oil.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapoxetine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Dapoxetine.Experimental
FluconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine.Approved, Illicit
FluindioneDapoxetine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Dapoxetine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dapoxetine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolDapoxetine may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapoxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapoxetine.Approved, Illicit, Investigational
FlurbiprofenDapoxetine may increase the antiplatelet activities of Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dapoxetine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluvoxamine.Approved, Investigational
ForasartanDapoxetine may increase the orthostatic hypotensive activities of Forasartan.Experimental
FosamprenavirThe serum concentration of Dapoxetine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dapoxetine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dapoxetine.Approved, Illicit, Investigational
FostamatinibDapoxetine may increase the orthostatic hypotensive activities of Fostamatinib.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapoxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Dapoxetine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Dapoxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dapoxetine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Dapoxetine.Investigational
GinsengDapoxetine may increase the antiplatelet activities of Ginseng.Approved, Investigational, Nutraceutical
GliclazideDapoxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDapoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDapoxetine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dapoxetine.Approved, Illicit
GlyburideDapoxetine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapoxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dapoxetine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapoxetine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dapoxetine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Dapoxetine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dapoxetine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Hydracarbazine.Experimental
HydralazineDapoxetine may increase the orthostatic hypotensive activities of Hydralazine.Approved
HydrochlorothiazideDapoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Dapoxetine.Approved, Illicit
HydroflumethiazideDapoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Dapoxetine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Dapoxetine.Approved
IbuprofenDapoxetine may increase the antiplatelet activities of Ibuprofen.Approved
IcosapentDapoxetine may increase the antiplatelet activities of Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Dapoxetine can be increased when it is combined with Idelalisib.Approved
IloperidoneDapoxetine may increase the orthostatic hypotensive activities of Iloperidone.Approved
ImatinibThe serum concentration of Dapoxetine can be increased when it is combined with Imatinib.Approved
ImidaprilDapoxetine may increase the orthostatic hypotensive activities of Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.Approved
IndalpineDapoxetine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideDapoxetine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Dapoxetine.Withdrawn
IndinavirThe serum concentration of Dapoxetine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Dapoxetine.Investigational
IndomethacinDapoxetine may increase the antiplatelet activities of Indomethacin.Approved, Investigational
IndoraminDapoxetine may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin AspartDapoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDapoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDapoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDapoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDapoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDapoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dapoxetine.Approved, Investigational
Ioflupane I-123Dapoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Dapoxetine.Withdrawn
IrbesartanDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Dapoxetine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapoxetine.Approved, Vet Approved
Isosorbide DinitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.Approved
IsradipineThe serum concentration of Dapoxetine can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Itraconazole.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapoxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dapoxetine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Dapoxetine.Approved, Investigational
KetoconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenDapoxetine may increase the antiplatelet activities of Ketoprofen.Approved, Vet Approved
KetorolacDapoxetine may increase the antiplatelet activities of Ketorolac.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolDapoxetine may increase the orthostatic hypotensive activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dapoxetine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Dapoxetine.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapoxetine.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be increased when it is combined with Dapoxetine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Dapoxetine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dapoxetine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Dapoxetine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dapoxetine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levodopa.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Dapoxetine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levorphanol.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Dapoxetine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapoxetine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Linezolid.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Dapoxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Dapoxetine.Approved
LiraglutideDapoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineDapoxetine may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilDapoxetine may increase the orthostatic hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lithium.Approved
LofentanilLofentanil may increase the serotonergic activities of Dapoxetine.Illicit
LopinavirThe serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Dapoxetine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dapoxetine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapoxetine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Dapoxetine.Approved
LornoxicamDapoxetine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LosartanDapoxetine may increase the orthostatic hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Dapoxetine can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapoxetine.Approved
LuliconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Luliconazole.Approved
LumiracoxibDapoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
Magnesium salicylateDapoxetine may increase the antiplatelet activities of Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Dapoxetine.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Dapoxetine.Experimental
MecaserminDapoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dapoxetine.Approved
Meclofenamic acidDapoxetine may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Dapoxetine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dapoxetine.Vet Approved
Mefenamic acidDapoxetine may increase the antiplatelet activities of Mefenamic acid.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dapoxetine.Approved, Nutraceutical, Vet Approved
MeloxicamDapoxetine may increase the antiplatelet activities of Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dapoxetine.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Dapoxetine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dapoxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Dapoxetine.Experimental
MesalazineDapoxetine may increase the antiplatelet activities of Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dapoxetine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.Approved
MetforminDapoxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Dapoxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dapoxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dapoxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapoxetine.Approved
MethotrimeprazineDapoxetine may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dapoxetine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.Approved
MethyclothiazideDapoxetine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dapoxetine.Experimental
Methylene blueDapoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dapoxetine.Approved
Methylpropylpropanediol dinitrateDapoxetine may increase the orthostatic hypotensive activities of Methylpropylpropanediol dinitrate.Experimental
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Dapoxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Metoclopramide.Approved, Investigational
MetolazoneDapoxetine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dapoxetine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dapoxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dapoxetine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolDapoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Dapoxetine.Approved
MinoxidilDapoxetine may increase the orthostatic hypotensive activities of Minoxidil.Approved, Investigational
MirodenafilDapoxetine may increase the orthostatic hypotensive activities of Mirodenafil.Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.Approved, Investigational
MoexiprilDapoxetine may increase the orthostatic hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dapoxetine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Dapoxetine.Approved, Investigational, Withdrawn
MorniflumateDapoxetine may increase the antiplatelet activities of Morniflumate.Approved
MorphineMorphine may increase the serotonergic activities of Dapoxetine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapoxetine.Approved, Investigational
NabumetoneDapoxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Dapoxetine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Dapoxetine.Approved
NaproxenDapoxetine may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Naratriptan.Approved, Investigational
NateglinideDapoxetine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Dapoxetine.Approved, Investigational
NefazodoneThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir.Approved
NepafenacDapoxetine may increase the antiplatelet activities of Nepafenac.Approved, Investigational
NetupitantThe serum concentration of Dapoxetine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Dapoxetine can be increased when it is combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nialamide.Withdrawn
NicardipineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolineDapoxetine may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Dapoxetine.Experimental
Niflumic AcidDapoxetine may increase the antiplatelet activities of Niflumic Acid.Approved
NiguldipineDapoxetine may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideDapoxetine may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.Approved
NitroglycerinDapoxetine may increase the orthostatic hypotensive activities of Nitroglycerin.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dapoxetine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Dapoxetine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Dapoxetine.Approved, Investigational
NormethadoneNormethadone may increase the serotonergic activities of Dapoxetine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Octamoxin.Withdrawn
OlaparibThe serum concentration of Dapoxetine can be increased when it is combined with Olaparib.Approved
OlmesartanDapoxetine may increase the orthostatic hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapoxetine.Approved
OmapatrilatDapoxetine may increase the orthostatic hypotensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ondansetron.Approved
OpiumOpium may increase the serotonergic activities of Dapoxetine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dapoxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine.Investigational
OxaprozinDapoxetine may increase the antiplatelet activities of Oxaprozin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Dapoxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dapoxetine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Dapoxetine.Approved, Investigational, Vet Approved
PaliperidoneDapoxetine may increase the orthostatic hypotensive activities of Paliperidone.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dapoxetine.Approved, Investigational
ParecoxibDapoxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Dapoxetine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Dapoxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Dapoxetine.Experimental
Pentaerythritol TetranitrateDapoxetine may increase the orthostatic hypotensive activities of Pentaerythritol Tetranitrate.Approved
PentamidineDapoxetine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapoxetine.Approved, Investigational, Vet Approved
PentoxifyllineDapoxetine may increase the orthostatic hypotensive activities of Pentoxifylline.Approved, Investigational
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Dapoxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Dapoxetine.Approved, Investigational
PerindoprilDapoxetine may increase the orthostatic hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dapoxetine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapoxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pethidine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Dapoxetine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Dapoxetine.Experimental
PhenindioneDapoxetine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapoxetine.Approved, Investigational
PhenoperidinePhenoperidine may increase the serotonergic activities of Dapoxetine.Experimental
PhenoxybenzamineDapoxetine may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dapoxetine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenoxypropazine.Withdrawn
PhenprocoumonDapoxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phentermine.Approved, Illicit
PhentolamineDapoxetine may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazoneDapoxetine may increase the antiplatelet activities of Phenylbutazone.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dapoxetine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dapoxetine.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Dapoxetine.Approved, Investigational
PioglitazoneDapoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapoxetine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Dapoxetine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Dapoxetine.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pirlindole.Approved
PiroxicamDapoxetine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pivhydrazine.Withdrawn
PizotifenDapoxetine may increase the orthostatic hypotensive activities of Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Dapoxetine.Experimental
PolythiazideDapoxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.Approved
PosaconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Dapoxetine.Approved
PramlintideDapoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dapoxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine.Approved, Illicit
PrazosinDapoxetine may increase the orthostatic hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapoxetine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dapoxetine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dapoxetine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Dapoxetine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapoxetine.Approved, Vet Approved
PromazineDapoxetine may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dapoxetine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Dapoxetine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Dapoxetine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dapoxetine.Approved, Vet Approved
Propatyl nitrateDapoxetine may increase the orthostatic hypotensive activities of Propatyl nitrate.Experimental, Investigational
PropericiazineDapoxetine may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineDapoxetine may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Dapoxetine.Vet Approved
PropiverineDapoxetine may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dapoxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dapoxetine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dapoxetine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Dapoxetine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dapoxetine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapoxetine.Approved, Illicit
QuetiapineDapoxetine may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinaprilDapoxetine may increase the orthostatic hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneDapoxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineDapoxetine may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
QuinineDapoxetine may increase the hypoglycemic activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Dapoxetine.Experimental
RacepinephrineDapoxetine may increase the orthostatic hypotensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Dapoxetine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine.Approved, Investigational
RamiprilDapoxetine may increase the orthostatic hypotensive activities of Ramipril.Approved
RanolazineThe serum concentration of Dapoxetine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Dapoxetine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine.Approved, Withdrawn
RepaglinideDapoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapoxetine.Approved, Investigational
ResveratrolDapoxetine may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Dapoxetine.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rizatriptan.Approved
RofecoxibDapoxetine may increase the antiplatelet activities of Rofecoxib.Approved, Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dapoxetine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine.Approved
RosiglitazoneDapoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RucaparibThe serum concentration of Dapoxetine can be increased when it is combined with Rucaparib.Approved, Investigational
SacubitrilDapoxetine may increase the orthostatic hypotensive activities of Sacubitril.Approved
SafinamideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Safrazine.Withdrawn
Salicylic acidDapoxetine may increase the antiplatelet activities of Salicylic acid.Approved, Investigational, Vet Approved
SalsalateDapoxetine may increase the antiplatelet activities of Salsalate.Approved
SaprisartanDapoxetine may increase the orthostatic hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.Approved, Investigational
SaralasinDapoxetine may increase the orthostatic hypotensive activities of Saralasin.Investigational
SaxagliptinDapoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Selegiline.Approved, Investigational, Vet Approved
SeliciclibDapoxetine may increase the antiplatelet activities of Seliciclib.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Dapoxetine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dapoxetine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapoxetine.Approved, Vet Approved
SildenafilThe serum concentration of Dapoxetine can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinDapoxetine may increase the orthostatic hypotensive activities of Silodosin.Approved
SimeprevirThe serum concentration of Dapoxetine can be increased when it is combined with Simeprevir.Approved
SitagliptinDapoxetine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Dapoxetine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Dapoxetine.Approved
SpiraprilDapoxetine may increase the orthostatic hypotensive activities of Spirapril.Approved
St. John's WortThe risk or severity of adverse effects can be increased when Dapoxetine is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Dapoxetine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Dapoxetine.Approved, Investigational
SulfadiazineDapoxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleDapoxetine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineDapoxetine may increase the antiplatelet activities of Sulfasalazine.Approved
SulfisoxazoleThe serum concentration of Dapoxetine can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacDapoxetine may increase the antiplatelet activities of Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dapoxetine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Dapoxetine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sumatriptan.Approved, Investigational
SunitinibDapoxetine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenDapoxetine may increase the antiplatelet activities of Suprofen.Approved, Withdrawn
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Dapoxetine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dapoxetine.Approved, Investigational
TadalafilDapoxetine may increase the orthostatic hypotensive activities of Tadalafil.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Dapoxetine.Investigational
TalniflumateDapoxetine may increase the antiplatelet activities of Talniflumate.Approved
TamsulosinDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Dapoxetine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Dapoxetine.Approved, Investigational
TasosartanDapoxetine may increase the orthostatic hypotensive activities of Tasosartan.Approved
TelaprevirThe serum concentration of Dapoxetine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Telithromycin.Approved
TelmisartanDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapoxetine.Approved, Investigational
TemocaprilDapoxetine may increase the orthostatic hypotensive activities of Temocapril.Experimental, Investigational
TenitramineDapoxetine may increase the orthostatic hypotensive activities of Tenitramine.Experimental
TenoxicamDapoxetine may increase the antiplatelet activities of Tenoxicam.Approved
TerazosinDapoxetine may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineThe serum concentration of Terbutaline can be increased when it is combined with Dapoxetine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Dapoxetine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapoxetine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dapoxetine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dapoxetine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dapoxetine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapoxetine.Approved, Investigational, Withdrawn
TheophyllineDapoxetine may increase the orthostatic hypotensive activities of Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dapoxetine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Dapoxetine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Dapoxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dapoxetine.Approved, Vet Approved
ThioproperazineDapoxetine may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineDapoxetine may increase the arrhythmogenic activities of Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapoxetine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Dapoxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dapoxetine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Dapoxetine.Approved, Investigational
Tiaprofenic acidDapoxetine may increase the antiplatelet activities of Tiaprofenic acid.Approved
TiclopidineThe serum concentration of Dapoxetine can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dapoxetine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Dapoxetine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Dapoxetine.Approved
TioclomarolDapoxetine may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.Approved, Investigational
TolazamideDapoxetine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineDapoxetine may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideDapoxetine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dapoxetine.Approved, Withdrawn
TolmetinDapoxetine may increase the antiplatelet activities of Tolmetin.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dapoxetine.Approved
TramadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.Approved, Investigational
TrandolaprilDapoxetine may increase the orthostatic hypotensive activities of Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.Approved, Investigational
TriamcinoloneDapoxetine may increase the antiplatelet activities of Triamcinolone.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapoxetine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Dapoxetine.Vet Approved
TrichlormethiazideDapoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Dapoxetine.Approved
TrifluoperazineDapoxetine may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Dapoxetine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine.Approved, Vet Approved
TrimazosinDapoxetine may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dapoxetine.Approved
Trolamine salicylateDapoxetine may increase the antiplatelet activities of Trolamine salicylate.Approved
TrolnitrateDapoxetine may increase the orthostatic hypotensive activities of Trolnitrate.Experimental
UdenafilDapoxetine may increase the orthostatic hypotensive activities of Udenafil.Approved, Investigational
UrapidilDapoxetine may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibDapoxetine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dapoxetine.Approved, Investigational
ValsartanDapoxetine may increase the orthostatic hypotensive activities of Valsartan.Approved, Investigational
VardenafilDapoxetine may increase the orthostatic hypotensive activities of Vardenafil.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Dapoxetine.Experimental
VerapamilThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dapoxetine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Dapoxetine.Experimental
VoriconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vortioxetine.Approved, Investigational
WarfarinDapoxetine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Dapoxetine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dapoxetine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapoxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Dapoxetine.Approved
ZimelidineDapoxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Dapoxetine can be increased when it is combined with Ziprasidone.Approved
ZofenoprilDapoxetine may increase the orthostatic hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dapoxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Zolmitriptan.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dapoxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dapoxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dapoxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dapoxetine.Approved, Investigational, Withdrawn
ZuclopenthixolDapoxetine may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Safarinejad MR: Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008 May;33(6):1259-65. Epub 2007 Jul 11. [PubMed:17625501]
  2. Cirillo-Penn K, Modi NB: Dapoxetine and paroxetine for the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):315. [PubMed:17909314]
  3. McMahon C: Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):314-5. [PubMed:17909313]
  4. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269]
  5. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37. [PubMed:16962882]
  6. Hellstrom WJ, Heintz JW: Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006 Nov;7(6):473-8. [PubMed:17052444]
  7. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K: Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007 Mar;47(3):315-22. [PubMed:17322143]
  8. Payne RE, Sadovsky R: Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007 May;74 Suppl 3:S47-53. [PubMed:17546831]
External Links
KEGG Drug
D03649
PubChem Compound
71353
PubChem Substance
175426887
ChemSpider
64453
ChEBI
135962
ChEMBL
CHEMBL2110900
PharmGKB
PA166151992
Wikipedia
Dapoxetine
ATC Codes
G04BX14 — Dapoxetine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDrug Interaction Potentiation2
1Unknown StatusTreatmentHealthy Male Subjects1
1, 2CompletedBasic SciencePremature Ejaculation1
3CompletedTreatmentEjaculation2
3CompletedTreatmentEjaculation / Erectile Dysfunction (ED) / Sexual Dysfunctions1
3CompletedTreatmentEjaculation / Sexual Dysfunctions1
3CompletedTreatmentErectile Dysfunction (ED)2
3CompletedTreatmentErectile Dysfunction (ED) / Sexual Dysfunctions1
3CompletedTreatmentSexual Dysfunction, Physiological1
Not AvailableNot Yet RecruitingNot AvailablePremature Ejaculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000837 mg/mLALOGPS
logP4.75ALOGPS
logP4.67ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity96.14 m3·mol-1ChemAxon
Polarizability35 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9758
Caco-2 permeable+0.817
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor IInhibitor0.6464
P-glycoprotein inhibitor IINon-inhibitor0.8833
Renal organic cation transporterInhibitor0.74
CYP450 2C9 substrateNon-substrate0.7484
CYP450 2D6 substrateSubstrate0.7615
CYP450 3A4 substrateSubstrate0.7727
CYP450 1A2 substrateInhibitor0.9354
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorNon-inhibitor0.5597
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8382
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6419
Ames testAMES toxic0.6626
CarcinogenicityNon-carcinogens0.8718
BiodegradationNot ready biodegradable0.9866
Rat acute toxicity2.5199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6032
hERG inhibition (predictor II)Inhibitor0.663
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Aralkylamines / Alkyl aryl ethers / Benzene and substituted derivatives / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Naphthalene / Aralkylamine / Alkyl aryl ether / Monocyclic benzene moiety / Tertiary aliphatic amine / Tertiary amine / Ether / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269]

Drug created on October 21, 2007 05:51 / Updated on June 02, 2018 07:36